The study concluded that patients with SLD and elevated serum IL-6 levels were at higher risk of experiencing severe illness from COVID-19, highlighting the connection between the inflammatory profile of SLD and the severity of COVID-19 clinical presentation. This evidence concerns the gene IL6 and COVID-19.